Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.76 percent. This is a 40.58 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $677.000 thousand which beat the analyst consensus estimate of $54.545 thousand by 1.14K percent.